Therapeutic Glypican‐3 CRISPR Genome‐Editing Using UltraLarge Porous Silica Nano‐Depot for the Treatment of Hepatocellular Carcinoma

CRISPR Gene Editing Ultra-large porous silica nano-depot (UPSND) enables the efficient delivery of large CRISPR-Cas9 proteins and sgRNA cassettes to target Glypican 3 in hepatocellular carcinoma cells. This genome editing strategy achieves significant tumor regression and prevents proliferation, while GPC3 deletion enhances immune cell infiltration into tumor tissues, indicating its potential for cancer immunotherapy. More in article number 2400447, Hyojin Lee, Seongchan Kim, Dong-Hyun Kim, and co-workers.